The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $478.09, reflecting a -1.02% shift from the previouse trading day's closing. This change lagged the S&P 500's 0 ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

New Century Financial Group LLC lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 25.1% during the 3rd quarter, according to its most recent disclosure with ...

Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) and keeping the price target at $473.00. Terence Flynn has given his Hold ...

Jessica Fye has given her Buy rating due to a combination of factors that highlight Vertex Pharmaceuticals’ promising developments, particularly concerning their drug suzetrigine. The recent ...

In the preceding three months, 19 analysts have released ratings for Vertex Pharmaceuticals VRTX, presenting a wide array of perspectives from bullish to bearish. The table below provides a ...

Deep-pocketed investors have adopted a bullish approach towards Vertex Pharmaceuticals VRTX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Using the 2 Stage Free Cash Flow to Equity, Vertex Pharmaceuticals fair value estimate is US$855 Current share price of US$483 suggests Vertex Pharmaceuticals is potentially 44% undervalued Analyst ...